Neurocognitive Impairment in Patients With COVID-19
Key facts
- Who runs it
- University of Rostock
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 118 people enrolled
- Started
- 15 Apr 2020
- Ended
- 31 Dec 2023
- Type of study
- Observational, 4 groups
- Record updated
- 29 January 2024
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- adult patients of every age
- admission to hospital with suspected COVID-19 disease
- confirmed SARS-CoV-2 infection within 48 hours after admission
Who cannot take part
- other acute central nervous system diseases (e.g. meningoencephalitis, intracerebral ischemia or hemorrhage)
- confirmed SARS-CoV-2 infection later than 48 hours after hospital admission
- transferral from another hospital
- participation in another interventional study
- no written informed consent from patient or legal representative
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging.
Read full original descriptionShow less
Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.
The 4 groups in the trial
- NCoV-A-COVID
* adult patients of every age * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission
- NCoV-A-CONTROL
* adult patients of every age * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission
- NCoV-P-COVID
* pediatric patients * admission to hospital with suspected COVID-19 disease * confirmed SARS-CoV-2 infection within 48 hours after admission
- NCoV-P-CONTROL
* pediatric patient * admission to hospital with suspected COVID-19 disease * exclusion of SARS-CoV-2 infection within 48 hours after admission
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study
- Publications
- Record updated
- 29 January 2024